ELN 14.46 1.11 / Elan Corp. PLC ADS FDA | Benzinga

Friday, March 16, 2012

Jefferies Comments on P3 Data for Bapineuzumab (Analyst Color, ELN, News, Reiteration, FDA, Analyst Ratings / Fri, 08:10am)

Thursday, January 26, 2012

Benzinga's M&A Chatter for Thursday January 26, 2012 (AMGN, CELG, ELN, IDIX, ILMN, JNJ, Long Ideas, MITI, MRK, News, RHHBY, SGEN, Short Ideas, Rumors, FDA, M&A, After-Hours Center, Movers, Tech, Media, Trading Ideas / Thu, 07:24pm)
From Earlier: Biogen Idec and Elan Corporation Announce ASCEND Study to Evaluate the Effectiveness of TYSABRI as a Treatment for Secondary-Progressive Multiple Sclerosis (BIIB, ELN, MS, News, RRMS, FDA / Thu, 09:53am)

Friday, January 20, 2012

Quest Diagnostics STRATIFY JCV First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients (BIIB, DGX, ELN, News, FDA / Fri, 05:00pm)

Wednesday, December 07, 2011

Elan Spokesperson Says No News Was Released Today to Account for Today's Price Spike (ELN, News, Rumors, FDA, Global, Movers, General / Wed, 01:30pm)

Thursday, October 20, 2011

From Earlier, Biogen Idec and Elan Receive Notification of PDUFA Date Extension (BIIB, ELN, News, FDA / Thu, 08:56am)

Wednesday, October 19, 2011

Biogen Idec and Elan Announce Data about Early Use and Long-Term Benefit of TYSABRI Presented at 5th Joint Triennial Congress of ECTRIMS and ACTRIMS (BIIB, ELN, News, FDA / Wed, 06:23am)

Thursday, October 29, 2009

FDA Confirms 24 total PML Cases Since Tysabri Re-Launched (BIIB, ELN, News, FDA / Thu, 12:31pm)